Abstract: Camptothecin (CPT) and its derivatives represent a potent class of anticancer agents that primarily target intracellular topoisomerase I. Despite their broad-spectrum antineoplastic activity, the clinical application of native CPT is severely hindered by its poor aqueous solubility, the inherent instability of its active lactone ring, and significant systemic toxicity. To overcome these pharmacological barriers, extensive research has focused on structural modifications and the development of advanced derivative formulations. This review synthesizes recent advancements in CPT derivative development, highlighting highly active analogs such as 10-hydroxycamptothecin (HCPT), SN-38, and exatecan derivatives (DXd). Furthermore, it explores the integration of these derivatives into cutting-edge delivery platforms, including antibody-drug conjugates (ADCs) and various nano-drug delivery systems (NDDS) such as polymeric nanoparticles, dendrimers, and liposomes. By examining the structure-activity relationships, molecular mechanisms, current clinical limitations, and future perspectives, this review provides a comprehensive overview of the trajectory of CPT-based therapeutics in modern oncology.
1. Introduction
Camptothecin (CPT) is a natural plant alkaloid originally isolated from the Chinese tree Camptotheca acuminata. It has long been recognized for its potent antitumor activity against a wide array of malignancies. Among its naturally occurring analogs, 10-hydroxycamptothecin (HCPT) is the most potent monomer, exhibiting an anticancer activity approximately 30 times greater than that of native CPT [2]. Despite their remarkable efficacy, the clinical translation of CPT and its early derivatives has been heavily restricted by severe physicochemical and pharmacokinetic limitations. Chief among these are extreme hydrophobicity, poor water solubility, and the rapid pH-dependent hydrolysis of the crucial lactone ring into an inactive and toxic carboxylate form under physiological conditions [2].
To harness the therapeutic potential of CPT while mitigating its drawbacks, contemporary research has pivoted toward structural modification and the development of sophisticated drug delivery systems. The advent of biomedical nanotechnology and targeted bioconjugates has facilitated the creation of novel CPT derivatives and formulations that significantly improve drug stability, enhance aqueous solubility, and promote tumor-specific accumulation [1][2]. This review delineates the progress in CPT structural modifications, focusing on derivative development, mechanism of action, and the integration of these compounds into modern nanomedicines and antibody-drug conjugates (ADCs).
2. Pharmacological Activity
CPT and its derivatives exhibit a broad and highly efficient anticancer spectrum. They have demonstrated potent apoptotic and antiproliferative abilities against various cancer cells and are clinically utilized or investigated for the treatment of colorectal cancer, liver cancer, gastric cancer, ovarian cancer, leukemia, head and neck tumors, breast cancer, and lung cancer [2][4][6]. Advanced synthetic derivatives, such as SN-38 (the active metabolite of irinotecan) and DXd (an exatecan derivative), are pharmacologically active at sub-nanomolar concentrations, making them exceptionally potent payloads for targeted therapies [7]. In addition to direct cytotoxicity, derivatives like HCPT have been shown to mediate antiproliferative effects through the induction of both apoptosis and autophagy in cancer cell lines [2].
3. Molecular Mechanism of Action
The primary molecular target of CPT and its structural analogs (including HCPT, SN-38, and DXd) is intracellular topoisomerase I (TOPO1), an essential enzyme responsible for relaxing DNA supercoiling during replication and transcription [2][7]. CPT derivatives bind to the TOPO1-DNA cleavable complex, stabilizing it and preventing the religation of the cleaved DNA strand. When the DNA replication fork collides with this stabilized complex, it results in lethal double-strand DNA breaks, ultimately triggering cell cycle arrest and apoptosis [2].
Beyond TOPO1 inhibition, recent formulations of CPT derivatives have been engineered to exert secondary mechanisms of action. For instance, certain supramolecular assemblies of HCPT can deplete cellular ATP, thereby reversing ATP-dependent drug efflux pumps and overcoming multidrug resistance [2]. Other nano-formulations co-delivering CPT derivatives with agents like dexamethasone or cinnamaldehyde can modulate the tumor microenvironment by generating reactive oxygen species (ROS) or reducing inflammation, further amplifying the apoptotic cascade [2].
4. Structure-Activity Relationship (SAR) and Derivative Development
The structural modification of CPT has been a focal point in oncology drug discovery, aiming to preserve the essential pharmacophore (the planar pentacyclic ring structure and the E-ring lactone) while improving solubility and targeting.
Small Molecule Derivatives: The addition of a hydroxyl group at the 10-position yields HCPT, which possesses superior potency and a broader therapeutic window compared to CPT [2]. Further modifications have led to SN-38 (7-ethyl-10-hydroxy-camptothecin) and DXd (an exatecan derivative). These analogs exhibit enhanced TOPO1 inhibition and are highly effective even in tumors resistant to earlier generations of CPTs [3][7].
Antibody-Drug Conjugates (ADCs): To overcome systemic toxicity, highly potent CPT derivatives are now frequently utilized as payloads in ADCs. For example, Sacituzumab govitecan utilizes SN-38 conjugated via a cleavable linker to an anti-TROP2 antibody, allowing for targeted delivery in triple-negative breast and urothelial cancers [4][6][7]. Similarly, Trastuzumab deruxtecan employs the DXd payload linked to a HER2-targeting antibody, demonstrating profound efficacy in HER2-positive malignancies [5][7]. The use of cleavable linkers in these ADCs ensures that the active CPT derivative is released specifically within the acidic or enzyme-rich tumor microenvironment [7].
Prodrugs and Nanocarriers: Structural modifications also include the synthesis of prodrugs and bioconjugates. For instance, CPT has been conjugated with α-lipoic acid and tetra(ethylene glycol) to form a ROS-responsive prodrug (CPT-TEG-ALA) that self-assembles into nanoprodrugs, significantly extending survival in glioblastoma models [3]. Furthermore, CPT and HCPT have been encapsulated in various nano-drug delivery systems (NDDS), including PEGylated nanoparticles, PLGA microspheres, liposomes, and dendrimers. A notable example is the conjugation of CPT to a PEG-PAMAM dendrimer functionalized with the AS1411 aptamer, which specifically targets nucleolin-overexpressing colorectal cancer cells, thereby delaying drug clearance and enhancing tumor-specific internalization [1].
5. Current Limitations
Despite significant advancements, the clinical application of CPT derivatives and their delivery systems faces several hurdles:
Systemic Toxicity: Even with targeted delivery, CPT derivatives can cause severe adverse effects. Irinotecan (CPT-11) and its active metabolite SN-38 are notorious for causing chemotherapy-induced intestinal mucositis (CIM), characterized by crypt apoptosis, villus atrophy, severe diarrhea, and weight loss due to oxidative stress and the downregulation of antioxidant enzymes [8]. Additionally, ADCs like Trastuzumab deruxtecan carry risks of severe pulmonary toxicities, including interstitial lung disease (ILD) and pneumonitis [5].
Delivery System Shortcomings: Many nanomedicines rely on the enhanced permeability and retention (EPR) effect for tumor targeting. However, the EPR effect is highly heterogeneous in human cancers compared to animal models, leading to poor tumor penetration and low clinical translation rates [2]. Furthermore, specific nanocarriers present unique challenges: PLGA and PLA nanoparticles often suffer from an initial uncontrolled "burst release" of the drug; liposomes can be unstable and leak prematurely; and dendrimers or inorganic nanoparticles (like gold or silica) may pose risks of long-term cytotoxicity, poor biodegradability, or rapid clearance by the reticuloendothelial system [2].
6. Future Perspectives
The future of CPT derivative development lies in refining targeted delivery and overcoming tumor resistance mechanisms. Key areas of future research include:
Stimuli-Responsive and Carrier-Free Systems: The development of "smart" nanocarriers that respond to specific tumor microenvironment triggers (such as pH, hypoxia, ROS, or specific enzymes like cathepsin B) will improve the spatial and temporal control of CPT release [2]. Additionally, carrier-free nanoparticles—formed by the self-assembly of pure drug molecules (e.g., HCPT co-assembled with photosensitizers or other chemotherapeutics)—offer a promising route to achieve exceptionally high drug loading capacities while avoiding carrier-induced toxicity [2].
Combination Therapies: Integrating CPT derivatives with other therapeutic modalities will be crucial. Co-delivery systems combining HCPT with small interfering RNA (siRNA), photodynamic therapy (PDT), photothermal therapy (PTT), or nitric oxide (NO) donors show great potential in reversing multidrug resistance and achieving synergistic tumor eradication [2].
Advanced Bioconjugation: For ADCs, future efforts will focus on optimizing the drug-to-antibody ratio (DAR) and engineering novel linker chemistries that provide high systemic stability while ensuring rapid, quantitative release of the CPT payload exclusively within the target cancer cells [7].
